<DOC>
	<DOCNO>NCT02971839</DOCNO>
	<brief_summary>This study evaluate efficacy safety CTP-656 patient cystic fibrosis ( CF ) cystic fibrosis transmembrane conductance regulator ( CFTR ) gate mutation .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CTP-656 Patients With Cystic Fibrosis With CFTR Gating Mutations</brief_title>
	<detailed_description>This randomize , parallel-group , double-blind , placebo control multicenter study evaluate safety efficacy CTP-656 CF patient CFTR gate mutation , compare Kalydeco , total 28 day . Subjects randomize receive either double-blind CTP-656 placebo , open-label Kalydeco .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>18 year age older Has confirm diagnosis CF least one allele follow CFTR gate mutation : G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R . Has stable Kalydeco therapy least 3 month prior screen Has FEV1 â‰¥ 60 % predict normal age , sex , height screen baseline ( Day 1 ) assessment Weighs least 40 kg screen Patients either gender woman childbearing potential must willing use medically highly effective form birth control treatment period 30 day last dose study treatment . Acute upper respiratory infection lower respiratory infection , pulmonary exacerbation , change therapy within 4 week study treatment Uncontrolled type 2 diabetes , uncontrolled CFrelated diabetes History hepatitis C chronic active hepatitis B infection History pulmonary tuberculosis , nontuberculosis mycobacterial infection allergic bronchopulmonary aspergillosis ( ABPA ) treat screen within 2 year prior screen Colonization B. cenocepacia , B. dolosa , B. multivorans , and/or M. abcessus within 2 year prior Screening Abnormal liver function History abnormal renal function History prolong QTcF &gt; 450 msec male QTcF &gt; 470 msec female History solid organ hematological transplantation Using inhibitor inducer cytochrome P450/3A study within 30 day screen Women pregnant lactating , plan become pregnant study within 1 month follow last dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>